PMC:7195088 / 6046-6268 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"156","span":{"begin":95,"end":103},"obj":"Species"},{"id":"192","span":{"begin":43,"end":53},"obj":"Chemical"},{"id":"216","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"Tax:9606"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:C000606551"},{"id":"A216","pred":"tao:has_database_id","subj":"216","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T25","span":{"begin":86,"end":94},"obj":"Disease"}],"attributes":[{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T21","span":{"begin":43,"end":53},"obj":"Chemical"}],"attributes":[{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature."}

{"project":"LitCovid-sentences","denotations":[{"id":"T43","span":{"begin":0,"end":222},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although promising in preclinical studies, remdesivir should be currently provided to COVID-19 patients only within RCT (preferentially) or compassionate-use/expanded-access programmes, owing to its investigational nature."}